Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

Dual-action eye drop targeting both evaporative and inflammatory dry eye disease moving to Phase 3 Positive Phase 1b results for ocular surface pain candidate validate TRPV1 antagonist approach and strengthen confidence in ongoing Phase 2 study Combined potential peak sales exceeding $2 billion assuming successful development and commercialization1 VAUGHAN, Ontario — Bausch + Lomb Corporation […]

We haven't written up this one. Financial Post has the full story — the link below goes straight to it.

Read the original at financialpost.com →

More in Health & Medicine

More from Monday 24 August →